{"id":"crisaborole-ointment-2-bid","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site burning"},{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By inhibiting PDE4, crisaborole increases intracellular cAMP levels in immune and inflammatory cells, leading to suppression of pro-inflammatory mediators such as TNF-α and IL-2. This mechanism reduces the inflammatory cascade characteristic of atopic dermatitis, providing topical anti-inflammatory effects without systemic corticosteroid exposure.","oneSentence":"Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:40.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT07367932","phase":"PHASE4","title":"Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Dermatitis, Atopic, Eczema","enrollment":30},{"nctId":"NCT07162896","phase":"PHASE3","title":"Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shalamar Institute of Health Sciences","startDate":"2026-06","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD)","enrollment":66},{"nctId":"NCT04194814","phase":"PHASE2","title":"Skin bioMARkers for Atopic Eczema Therapy Evaluation","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2020-11-20","conditions":"Atopic Eczema/Dermatitis (Non-Specific)","enrollment":37},{"nctId":"NCT05200403","phase":"PHASE4","title":"Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-07-26","conditions":"Atopic Dermatitis","enrollment":72},{"nctId":"NCT05298033","phase":"PHASE2","title":"Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-09-07","conditions":"Vitiligo","enrollment":32},{"nctId":"NCT04040192","phase":"PHASE3","title":"A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-09-12","conditions":"Atopic Dermatitis","enrollment":620},{"nctId":"NCT04023084","phase":"PHASE4","title":"Response of Children With Atopic Dermatitis (Eczema) to Eucrisa","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2019-10-03","conditions":"Atopic Dermatitis, Eczema","enrollment":30},{"nctId":"NCT04360187","phase":"PHASE3","title":"Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-27","conditions":"Atopic Dermatitis","enrollment":391},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT04498403","phase":"PHASE3","title":"A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-09-14","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT04008784","phase":"","title":"Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period","status":"COMPLETED","sponsor":"Clinical Research Center of the Carolinas","startDate":"2019-09-16","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT03351114","phase":"PHASE2","title":"Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-09-01","conditions":"Morphea","enrollment":8},{"nctId":"NCT04214197","phase":"PHASE4","title":"Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-02-03","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT03954158","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-15","conditions":"Atopic Dermatitis","enrollment":81},{"nctId":"NCT03356977","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-16","conditions":"Atopic Dermatitis","enrollment":137},{"nctId":"NCT03233529","phase":"PHASE2","title":"Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-31","conditions":"Dermatitis, Atopic","enrollment":40},{"nctId":"NCT01258088","phase":"PHASE1","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11-30","conditions":"Plaque-type Psoriasis","enrollment":16},{"nctId":"NCT01301508","phase":"PHASE2","title":"Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Dermatitis, Atopic","enrollment":46},{"nctId":"NCT01652885","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Dermatitis, Atopic","enrollment":23},{"nctId":"NCT01300052","phase":"PHASE2","title":"AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01-26","conditions":"Psoriasis","enrollment":68},{"nctId":"NCT01029405","phase":"PHASE2","title":"Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Psoriasis","enrollment":145},{"nctId":"NCT01602341","phase":"PHASE2","title":"Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Dermatitis, Atopic","enrollment":86},{"nctId":"NCT00755196","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02118766","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":763},{"nctId":"NCT02118792","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":764},{"nctId":"NCT00759161","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Psoriasis","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Crisaborole ointment 2% BID","genericName":"Crisaborole ointment 2% BID","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in the skin. Used for Atopic dermatitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}